Summary
- Johnson & Johnson has seen a real growth slowdown at the end of 2018.
- Investors should embrace themselves for lower growth in 2019 as well.
- Slower growth and recent turmoil regarding asbestos claims make me cautious as shares have held up quite well.
- Looking for a community to discuss ideas with? Value In Corporate Events features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Johnson & Johnson (JNJ) has seen some growth deceleration towards the end of 2018, a trend which the company expects to last into 2019, which should be concerning to investors. In the time frame of just a few months, Johnson & Johnson has gone from a strong solid organic growth play to a diversified operation showing less growth and having to deal with asbestos risks as well, as reports scared the financial community back In December.
Nonetheless, shares are holding up pretty well, a bit too good, if you ask me. While valuations still look very reasonable, I see no triggers on the horizon to buy shares at this point in time.
